The Effectiveness of Platelet-Rich Plasma Injections in Gluteal Tendonopathy – A Randomised, Double-Blind Controlled Trial

Phase 3

Completed

• Conditions: Gluteal Tendonopathy; Musculoskeletal - Other muscular and skeletal disorders

• Registration Number: ACTRN12613000677707
• Lead Sponsor: Dr Jane Fitzpatrick

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-06-20
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Trial patients can be men or women, aged between 18 and 80 years inclusive, with gluteus medius and/or minimus tendonopathy

Exclusion Criteria

tears of the tendons on MRI and ultrasound, a history of breast cancer, previous hip surgery, current warfarin treatment, recent back surgery or sciatic pain, or cortisone treatment in the previous six weeks

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change from baseline in Modified Harris Hip Score, assessing patient ratings of hip function, pain and activity.[12 weeks post-intervention]

Secondary Outcome Measures

Name	Time	Method
Safety - occurrence of adverse events. Patients will be asked about possible adverse events at each patient follow-up, and also encouraged to report them to the investigators at any time during the trial. No adverse events have been pre-specified as likely.[Throughout the trial, in particular at each patient follow-up. Patients will be asked about possible adverse events, and also encouraged to report them to the investigators at any time during the trial. Follow-up of patients will take place 2 weeks, 6 weeks, 3 months and 12 months post-treatment. Total planned trial duration is 12 months.]